This strategy was used in a study of glioblastoma, where it was observed that a CD47 monoclonal antibody converted tumor-promoting TAMs to an anti-tumor phenotype that exhibited enhanced phagocytosis of cancer cells (127). Here, CD47 is linked to cancer.